Patent 12576080

Derivative works

Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.

Active provider: Google · gemini-2.5-flash

Derivative works

Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.

✓ Generated

As a Senior Patent Strategist and Research Engineer specializing in Defensive Publishing, I will generate derivative variations for US patent 12576080. Due to the absence of a formal "Claims" section in the provided authoritative patent text, I will proceed by identifying the core inventive concepts and embodiments described in the "SUMMARY OF THE INVENTION" and "DETAILED DESCRIPTION OF THE INVENTION" sections, and treat these as the foundational elements for generating derivative disclosures.

The primary inventive concepts of US12576080 can be generalized as:

  1. Core Concept (Method): A method of increasing tear production, treating dry eye, or improving ocular comfort/health by locally administering a therapeutically effective amount of a nicotinic acetylcholine receptor (nAChR) agonist (such as varenicline) into the nasal cavity, wherein the agonist is characterized by selective binding to peripheral nAChR, minimal crossing of the blood-brain barrier, and/or minimal systemic bioavailability/psychoactive side effects. This method aims to activate the trigeminal nerve and/or nasolacrimal reflex.
  2. Core Concept (Formulation): A pharmaceutical formulation for local nasal administration comprising a nAChR agonist (such as varenicline) and optionally one or more substances designed to prevent or facilitate recovery from nAChR desensitization (e.g., PKC activators, PKA activators, or calcineurin inhibitors like cyclosporine).

Herein, I disclose derivative variations for these core concepts to create defensive prior art, aiming to render future incremental improvements by competitors obvious or non-novel.

Derivative Disclosures for Core Concept 1 (Method)

Core Concept 1: A method of increasing tear production, treating dry eye, or improving ocular comfort/health by locally administering a therapeutically effective amount of a nicotinic acetylcholine receptor (nAChR) agonist (such as varenicline) into the nasal cavity, wherein the agonist is characterized by selective binding to peripheral nAChR, minimal crossing of the blood-brain barrier, and/or minimal systemic bioavailability/psychoactive side effects. This method aims to activate the trigeminal nerve and/or nasolacrimal reflex.

1. Material & Component Substitution

Derivative 1.1: Alternative Peripheral nAChR Agonists

Enabling Description: The method of activating the nasolacrimal reflex via nasal administration can be extended to other highly selective peripheral nAChR agonists beyond varenicline. Specifically, this includes novel synthetic quinuclidine derivatives that exhibit high affinity for α3β4 and α7 nAChR subtypes, and possess a high polar surface area (PSA) exceeding 120 Ų or a calculated logP less than 0.5, thereby substantially limiting passive diffusion across the blood-brain barrier. Such compounds, when formulated as an aqueous solution with a pH between 6.0 and 7.5 and administered via a metered-dose nasal spray device delivering 25 µL per actuation, would selectively stimulate nasal trigeminal nerve endings to evoke reflex lacrimation without systemic or central nervous system (CNS) side effects. An example could involve a methylated derivative of lobeline specifically engineered for increased polarity.

flowchart TD
    A[Individual in need of tear production] --> B{Nasal Administration Device};
    B -- Delivers --> C[Aqueous solution of highly polar nAChR agonist (e.g., methylated lobeline)];
    C --> D[Nasal Mucosa: Peripheral nAChR Activation];
    D --> E[Trigeminal Nerve Stimulation];
    E --> F[Nasolacrimal Reflex Arc];
    F --> G[Lacrimal Gland Activation];
    G --> H[Increased Tear Production];
    style B fill:#f9f,stroke:#333,stroke-width:2px
    style C fill:#ccf,stroke:#333,stroke-width:2px

Derivative 1.2: Advanced Nasal Delivery Systems with Bioadhesive Polymers

Enabling Description: The local nasal administration of varenicline or a similar nAChR agonist can be enhanced using advanced delivery systems incorporating bioadhesive or mucoadhesive polymers. This involves formulating varenicline (e.g., at 0.1% w/v concentration) in a thermosensitive hydrogel composed of poloxamer 407 and polycarbophil. At room temperature, the formulation is a liquid, but it rapidly transitions to a gel upon contact with the nasal mucosa (due to body temperature), increasing retention time and localized drug concentration. This ensures prolonged interaction with peripheral nAChRs on the trigeminal nerve endings, maximizing reflex stimulation while minimizing post-nasal drip and systemic absorption. The delivery device would be a precision atomization pump capable of dispensing a fine mist (particle size 20-50 µm) to ensure broad coverage of the nasal turbinates.

flowchart TD
    A[Varenicline Aqueous Solution] --> B{Add Bioadhesive Polymers: Poloxamer 407, Polycarbophil};
    B --> C[Thermosensitive Liquid Formulation];
    C --> D{Nasal Atomization Pump};
    D -- Dispenses Mist --> E[Nasal Cavity: Liquid contacts Mucosa];
    E -- Temperature Change --> F[Gelation on Mucosa];
    F -- Prolonged Release --> G[Peripheral nAChR Activation];
    G --> H[Nasolacrimal Reflex];
    H --> I[Increased Tear Production];
    style D fill:#f9f,stroke:#333,stroke-width:2px
    style F fill:#ccf,stroke:#333,stroke-width:2px

2. Operational Parameter Expansion

Derivative 1.3: Pulsed Micro-Dosing for Receptor Dynamics Optimization

Enabling Description: Instead of continuous or fixed-interval dosing, the method can employ a pulsed micro-dosing regimen, where ultralow doses (e.g., 0.1-1.0 µg of varenicline) are administered with precisely controlled intervals (e.g., 5-minute pulses over a 30-minute period, followed by a 4-hour refractory period). This strategy is designed to exploit the rapid desensitization and resensitization kinetics of peripheral nAChRs, ensuring maximal receptor activation during the brief "open" state and allowing sufficient recovery time to prevent prolonged desensitization. The administration device would be a programmable micro-nebulizer integrated with a piezoelectric actuator, capable of delivering highly reproducible, precise micro-volumes at user-defined frequencies, potentially optimizing the tear production response curve based on individual patient physiology.

sequenceDiagram
    participant P as Patient
    participant D as Micro-Nebulizer Device
    participant N as Nasal nAChR
    participant T as Trigeminal Nerve
    P->>D: Initiate treatment cycle
    loop 5-min pulses for 30 min
        D->>N: Deliver 0.5 µg Varenicline (Pulse)
        N->>T: Activate (Rapid Onset)
        T->>P: Increased Tear Production (Peak)
        N-->>N: Desensitization (Partial)
        D->>D: Wait 5 minutes
    end
    N-->>N: Resensitization (during 4-hr refractory period)
    P->>D: Next treatment cycle after 4 hours

Derivative 1.4: Extreme Environmental Adaptation (High Altitude/Low Humidity)

Enabling Description: The method is adapted for individuals operating in extreme environments characterized by significantly reduced atmospheric pressure and humidity, such as high-altitude (e.g., >10,000 feet above sea level) or arid desert conditions. The formulation comprises a hyperosmolar varenicline solution (e.g., 0.3% w/v varenicline in a 0.5 M NaCl solution) to counteract mucosal dehydration and promote rapid absorption in desiccated nasal passages. The administration is via a portable, pressure-regulated nasal spray device that ensures consistent droplet size and spray pattern despite ambient pressure fluctuations. The regimen involves proactive administration (e.g., every 2 hours) to maintain ocular surface protection before symptoms manifest, thereby preventing environmentally-induced DED.

stateDiagram-v2
    state Environment {
        HighAltitude --> LowHumidity: Concurrent
    }
    state PatientConditions {
        LowHumidity --> NasalDehydration: Leads to
        NasalDehydration --> OcularSurfaceStress: Aggravates
    }
    state DeviceOperation {
        PressureRegulatedDevice --> ConsistentSpray: Ensures
        ConsistentSpray --> HyperosmolarSolution: Delivers
    }
    state TherapeuticEffect {
        HyperosmolarSolution --> RapidMucosalAbsorption: Enhances
        RapidMucosalAbsorption --> Peripheral_nAChR_Activation
        Peripheral_nAChR_Activation --> NasolacrimalReflex: Initiates
        NasolacrimalReflex --> OcularProtection: Achieves
    }
    [*] --> Environment
    Environment --> PatientConditions
    PatientConditions --> DeviceOperation
    DeviceOperation --> TherapeuticEffect
    OcularProtection --> [*]

3. Cross-Domain Application

Derivative 1.5: AgTech - Plant Stress Response Modulation

Enabling Description: The principle of local neural activation via a receptor agonist, leading to a reflex response, can be applied in AgTech for modulating plant stress responses. Specifically, a nicotinic acetylcholine receptor (nAChR) agonist, potentially a derivative of varenicline optimized for plant nicotinic receptor homologs (e.g., plant-specific nAChR-like proteins), is locally administered to specific foliar stomata or root hair cells via a micro-aerosol or localized drip irrigation system. This triggers a localized osmotic stress response or abscisic acid (ABA) pathway activation in a specific leaf or root zone, leading to enhanced water retention in that localized region or targeted nutrient uptake, without affecting the entire plant's growth kinetics or requiring systemic pesticide/herbicide application. The device would involve a drone-mounted, precision micro-spray nozzle for targeted foliar delivery, or a subsurface micro-irrigation emitter for root application.

flowchart LR
    A[Varenicline Analog (Plant-optimized)] --> B{Micro-Aerosol/Drip System};
    B --> C[Localized Plant Tissue (Stomata/Root Hairs)];
    C -- Activates --> D[Plant nAChR Homologs];
    D -- Triggers --> E[Localized Stress Signaling Pathway (e.g., ABA pathway)];
    E --> F[Enhanced Water Retention / Targeted Nutrient Uptake];
    style B fill:#f9f,stroke:#333,stroke-width:2px
    style F fill:#ccf,stroke:#333,stroke-width:2px

Derivative 1.6: Animal Care - Equine Tear Production for Ocular Health

Enabling Description: A method for treating dry eye in domestic animals, specifically horses (equine dry eye disease), by local intranasal administration of varenicline. Given the larger nasal cavity and distinct trigeminal nerve anatomy in equines, the formulation comprises a higher concentration of varenicline (e.g., 0.5% w/v) in a buffered saline solution optimized for equine nasal pH (typically slightly alkaline, pH 7.5-8.0). The administration device is a specialized equine nasal nebulizer with an elongated nozzle and high-volume atomization capability (e.g., 200 µL per nostril) to ensure adequate distribution across the ethmoid turbinates where the trigeminal nerve endings are abundant. Dosing is once daily, adapting for the physiological differences in drug absorption and reflex pathway sensitivity in horses, resulting in increased basal and reflex tear secretion to alleviate keratoconjunctivitis sicca (KCS) symptoms in equines.

classDiagram
    class EquinePatient {
        +EquineDryEyeDisease
        +NasalCavity_Large
        +EthmoidTurbinates_Target
    }
    class VareniclineFormulation {
        +Concentration_0_5pct_w_v
        +pH_7_5_8_0
        +BufferedSalineSolution
    }
    class EquineNasalNebulizer {
        +ElongatedNozzle
        +HighVolumeAtomization_200uL
        +TargetedDelivery
    }
    class Mechanism {
        +Peripheral_nAChR_Activation
        +TrigeminalNerveStimulation
        +NasolacrimalReflex
        +IncreasedTearProduction
    }
    EquinePatient "1" -- "*" VareniclineFormulation : Receives
    EquinePatient "1" -- "1" EquineNasalNebulizer : Administered by
    VareniclineFormulation "1" -- "1" Mechanism : Drives
    EquineNasalNebulizer "1" -- "1" Mechanism : Facilitates
    Mechanism "1" -- "1" EquinePatient : Benefits

4. Integration with Emerging Tech

Derivative 1.7: AI-Driven Personalized Dosing with Real-time Ocular Surface Monitoring

Enabling Description: The method integrates an AI-driven personalized dosing algorithm with real-time ocular surface monitoring via IoT sensors. A miniaturized, non-invasive ocular sensor (e.g., embedded in a contact lens or attached to the lower eyelid margin) continuously measures tear film osmolarity, blink rate, and baseline tear volume. This data is transmitted wirelessly to a smartphone application running an AI algorithm. The AI analyzes the data, predicts the optimal varenicline micro-dose (e.g., 5-50 µg) and administration interval required to maintain tear film homeostasis, and sends a command to a smart nasal spray device. The smart device precisely dispenses the AI-determined dose, ensuring dynamic therapeutic adjustment based on individual, fluctuating ocular needs, thereby preventing over- or under-dosing and optimizing therapeutic efficacy while minimizing desensitization risks.

sequenceDiagram
    participant O as Ocular IoT Sensor
    participant S as Smartphone App (AI Engine)
    participant D as Smart Nasal Spray Device
    participant P as Patient
    participant N as Nasal nAChR
    O->>S: Transmit Real-time Tear Data (osmolarity, blink rate)
    S->>S: AI Algorithm Analyzes Data
    S->>S: AI Determines Optimal Varenicline Dose & Interval
    S->>D: Send Dosing Command
    D->>P: Administer Precise Varenicline Dose (e.g., 10 µg)
    P->>N: Varenicline reaches Nasal Mucosa
    N->>P: Triggers Tear Production
    P->>O: Ocular State Changes (Improved)
    Note over S: Continuous Learning & Optimization

5. The "Inverse" or Failure Mode

Derivative 1.8: Diagnostic Nasal Challenge Test for Neuropathic Dry Eye

Enabling Description: An "inverse" application of the method involves using a sub-therapeutic dose of varenicline delivered nasally as a diagnostic challenge. This is designed to assess the integrity and responsiveness of the nasolacrimal reflex arc in patients suspected of having neuropathic dry eye, where sensory nerve damage might impair tear production despite intact lacrimal glands. A very low, standardized dose of varenicline (e.g., 0.5 µg) is administered via a single-dose nasal pipette. Tear production is then measured over 5-10 minutes using a Schirmer's test. A minimal or absent increase in tear production post-challenge would indicate impairment of the trigeminal nerve or its reflex pathway, differentiating it from purely aqueous-deficient dry eye. The device is designed for a single, non-refillable, precision dose to ensure safety and prevent therapeutic effect.

graph TD
    A[Patient Suspected Neuropathic DED] --> B{Administer Sub-therapeutic Varenicline Dose (0.5µg) via Pipette};
    B --> C[Nasal Mucosa: Attempted Peripheral nAChR Activation];
    C --> D{Monitor Tear Production (Schirmer's Test 5-10 min post-admin)};
    D -- Significant Increase --> E[Functional Reflex Arc];
    D -- Minimal/No Increase --> F[Impaired Reflex Arc (Neuropathic DED)];
    style E fill:#ccf,stroke:#333,stroke-width:2px
    style F fill:#f9f,stroke:#333,stroke-width:2px

Derivative Disclosures for Core Concept 2 (Formulation)

Core Concept 2: A pharmaceutical formulation for local nasal administration comprising a nAChR agonist (such as varenicline) and optionally one or more substances designed to prevent or facilitate recovery from nAChR desensitization (e.g., PKC activators, PKA activators, or calcineurin inhibitors like cyclosporine).

1. Material & Component Substitution

Derivative 2.1: Varenicline Prodrug with PKA Up-modulator in Lyophilized Powder

Enabling Description: A novel nasal formulation comprising a varenicline prodrug (e.g., an ester derivative that is enzymatically cleaved in situ on the nasal mucosa to release active varenicline) combined with a PKA up-modulating peptide (e.g., a cell-permeable peptide corresponding to a PKA regulatory subunit domain that enhances PKA activity). The formulation is presented as a lyophilized powder for nasal insufflation, packaged in a single-use capsule. Upon administration via a dry powder inhaler, the powder adheres to the mucosa. The prodrug ensures sustained release of varenicline, while the PKA up-modulator actively phosphorylates nAChRs, preventing or reducing desensitization and thereby prolonging the therapeutic effect of tear production. This allows for less frequent dosing (e.g., once daily) compared to aqueous solutions.

flowchart TD
    A[Varenicline Prodrug (e.g., ester)] --> B{PKA Up-modulating Peptide};
    B --> C[Lyophilized Powder Formulation];
    C --> D{Dry Powder Nasal Inhaler};
    D -- Insufflates --> E[Nasal Mucosa];
    E -- Cleavage --> F[Active Varenicline];
    E -- Absorption --> G[PKA Up-modulator];
    F & G --> H[Sustained Peripheral nAChR Activation & Desensitization Prevention];
    H --> I[Enhanced Tear Production];
    style C fill:#ccf,stroke:#333,stroke-width:2px
    style D fill:#f9f,stroke:#333,stroke-width:2px

Derivative 2.2: Sustained-Release Cyclosporine Co-Formulation with Nicotine Salts

Enabling Description: A pharmaceutical formulation for local nasal administration comprising a highly water-soluble nicotine salt (e.g., nicotine bitartrate, 0.05% w/v) as the nAChR agonist, co-formulated with a sustained-release, mucoadhesive cyclosporine derivative (e.g., cyclosporine A encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles, 0.05% w/v). The formulation is presented as an emulsion spray. The immediate release of nicotine provides rapid onset of tear production, while the PLGA-encapsulated cyclosporine nanoparticles provide continuous, low-level local immunosuppression and calcineurin inhibition, thus preventing nAChR desensitization over an extended period (e.g., 12-24 hours). This dual-action approach maintains receptor sensitivity and tear production efficacy with reduced dosing frequency.

classDiagram
    class NicotineSalt {
        +NicotineBitartrate
        +RapidRelease
        +Peripheral_nAChR_Agonist
    }
    class CyclosporineNanoParticle {
        +CyclosporineA
        +PLGANanoencapsulation
        +SustainedRelease
        +CalcineurinInhibitor
        +PreventsDesensitization
    }
    class EmulsionSprayFormulation {
        +DualActiveIngredients
        +MucoadhesiveProperties
    }
    NicotineSalt "1" -- "*" EmulsionSprayFormulation : Contained in
    CyclosporineNanoParticle "1" -- "*" EmulsionSprayFormulation : Contained in
    EmulsionSprayFormulation --> Peripheral_nAChR_Activation : Enables
    EmulsionSprayFormulation --> Receptor_Desensitization_Prevention : Enables

2. Operational Parameter Expansion

Derivative 2.3: Cryopreserved Varenicline/PKC Activator Nasal Insert

Enabling Description: A pharmaceutical formulation designed for stability and efficacy under extreme storage conditions. Varenicline (0.1% w/v) is combined with a membrane-permeable PKC activator (e.g., phorbol 12-myristate 13-acetate (PMA) at 100 nM) in a proprietary excipient matrix. This matrix is then manufactured as a small, dissolvable nasal insert (e.g., 5x2x1 mm), hermetically sealed, and cryopreserved in liquid nitrogen during storage and transport. Upon thawing and insertion into the nasal cavity, the insert rapidly dissolves, releasing the active ingredients. The cryopreservation ensures maximal stability of both varenicline and the PKC activator, especially in environments lacking controlled temperature, preserving drug potency over extended periods (e.g., several years) for use in remote or disaster relief scenarios where drug degradation is a major concern.

stateDiagram-v2
    state Formulation_Preparation {
        Varenicline + PKC_Activator --> Excipient_Matrix
        Excipient_Matrix --> Nasal_Insert_Formation
        Nasal_Insert_Formation --> Hermetic_Sealing
    }
    state Storage {
        Hermetic_Sealing --> Cryopreservation_LN2: Extended shelf-life
    }
    state Usage {
        Cryopreservation_LN2 --> Thawing: Prior to use
        Thawing --> Nasal_Insertion
        Nasal_Insertion --> Rapid_Dissolution
        Rapid_Dissolution --> Active_Ingredient_Release
        Active_Ingredient_Release --> nAChR_Activation_Prevention_Desensitization
    }
    [*] --> Formulation_Preparation
    Formulation_Preparation --> Storage
    Storage --> Usage
    nAChR_Activation_Prevention_Desensitization --> [*]

3. Cross-Domain Application

Derivative 2.4: Formulation for Veterinary Use in Avian Species (Poultry Dry Eye)

Enabling Description: A specialized formulation for treating ocular conditions, such as "dry eye" or respiratory-ocular irritation, in avian species (e.g., commercial poultry in large-scale farming environments) where air quality and ventilation can lead to widespread ocular issues. The formulation comprises a lower concentration of varenicline (e.g., 0.01% w/v) and a mucin-stimulating agent (e.g., a glycosaminoglycan like hyaluronate) in a large-volume, fine-mist aerosol compatible with farm-scale environmental control systems. This formulation is delivered via an automated, timed-release environmental nebulization system distributed throughout poultry houses, ensuring uniform, low-dose exposure to the entire flock. The varenicline stimulates tear/mucin production via the avian equivalent of the nasolacrimal reflex, and hyaluronate enhances ocular surface hydration and protection, mitigating stress-induced ocular pathologies.

flowchart TD
    A[Varenicline (0.01%)] --> B{Mucin-Stimulating Agent (Hyaluronate)};
    B --> C[Large-Volume Fine-Mist Aerosol Formulation];
    C --> D{Automated Environmental Nebulization System (Poultry House)};
    D -- Uniform Release --> E[Avian Nasal/Ocular Mucosa Exposure];
    E --> F[Avian nAChR Activation & Mucin Secretion];
    F --> G[Increased Ocular Hydration & Protection];
    style C fill:#ccf,stroke:#333,stroke-width:2px
    style D fill:#f9f,stroke:#333,stroke-width:2px

Derivative 2.5: Industrial Safety - Ocular Protection for Cleanroom Technicians

Enabling Description: A nasal formulation to protect the ocular surface of industrial cleanroom technicians subjected to extremely dry, filtered air and prolonged visual focus, which can induce dry eye symptoms. The formulation contains a low-dose nAChR agonist (e.g., cytisine, 0.02% w/v) for tear stimulation, combined with an osmotic agent (e.g., trehalose 2% w/v) and a mild anti-inflammatory agent (e.g., a low concentration of a corticosteroid, 0.005% w/v, designed for minimal systemic absorption). This is formulated as a non-irritating, pH-neutral, preservative-free nasal gel for application via a single-dose tube twice daily. The gel provides sustained contact with nasal mucosa, stimulating tear production and delivering localized anti-inflammatory effects to protect the ocular surface from environmental stressors.

classDiagram
    class Cytisine {
        +Peripheral_nAChR_Agonist
    }
    class Trehalose {
        +OsmoticAgent
    }
    class Corticosteroid {
        +AntiInflammatory
        -MinimalSystemicAbsorption
    }
    class NasalGelFormulation {
        +pH_Neutral
        +Preservative_Free
        +SustainedRelease
    }
    class CleanroomTechnician {
        +Environment_DryFilteredAir
        +SustainedVisualFocus
        +RequiresOcularProtection
    }
    Cytisine "1" -- "*" NasalGelFormulation : Included in
    Trehalose "1" -- "*" NasalGelFormulation : Included in
    Corticosteroid "1" -- "*" NasalGelFormulation : Included in
    NasalGelFormulation --> CleanroomTechnician : Protects

4. Integration with Emerging Tech

Derivative 2.6: Blockchain-Verified Supply Chain for Temperature-Sensitive Nasal Formulations

Enabling Description: A pharmaceutical formulation for varenicline (0.1% w/v) with a desensitization-preventing agent (e.g., cyclosporine A 0.09% w/v) packaged in a smart nasal spray device. The formulation is highly temperature-sensitive. Its entire supply chain, from manufacturing to patient delivery, is tracked via a blockchain ledger. Each batch of formulation is embedded with an NFC tag that, when scanned, records real-time temperature and humidity data onto the blockchain. Smart contracts on the blockchain automatically trigger alerts if temperature excursions exceed predefined thresholds (e.g., above 25°C for more than 4 hours), potentially invalidating the batch for distribution or flagging it for discard. This ensures the integrity and efficacy of the temperature-sensitive formulation, especially in global distribution networks prone to varied environmental conditions, preventing the administration of degraded product to patients.

graph TD
    A[Manufacturing Batch (Varenicline + Cyclosporine)] --> B{Embed NFC Temperature/Humidity Sensor};
    B --> C[Package in Smart Nasal Spray Device];
    C --> D{Distributor Warehouse: Scan NFC - Record to Blockchain};
    D -- Temperature Excursion Detected --> E{Smart Contract Alert: Batch Invalidated};
    D -- No Excursion --> F{Pharmacy: Scan NFC - Record to Blockchain};
    F --> G{Patient: Use Device - Optional NFC Scan for Compliance};
    E -- Disposition --> H[Recall / Dispose Batch];
    F --> I[Safe Administration];

5. The "Inverse" or Failure Mode

Derivative 2.7: Low-Power/Limited-Functionality Formulation for Mild Symptoms

Enabling Description: A low-strength, self-regulating varenicline formulation (e.g., 0.005% w/v) contained within a nasal device designed for "low-power" or "limited-functionality" mode, specifically for individuals experiencing only mild or intermittent dry eye symptoms. The device includes a passive, humidity-sensitive valve that only releases the active ingredient when the ambient humidity in the nasal cavity drops below a certain threshold (e.g., 60% relative humidity), thus self-modulating dosing frequency to respond solely to physiological need. This prevents unnecessary administration and minimizes the risk of desensitization or other side effects in individuals who do not require consistent, robust tear production, effectively providing a "demand-responsive" therapy without active patient intervention for milder cases.

stateDiagram-v2
    state Device_In_NasalCavity {
        Active : Monitoring Nasal Humidity
    }
    state Humid_Environment {
        Active --> Idle: Humidity > 60%
        Idle --> Active: Humidity drops
    }
state Dry_Environment {
        Active --> Release_Varenicline: Humidity <= 60%
        Release_Varenicline --> Idle: Dose administered
    }
    Idle --> Monitoring_Nasal_Humidity: Loop
    Release_Varenicline --> Initiate_Tear_Production
    Initiate_Tear_Production --> Relieve_Mild_Symptoms
    Relieve_Mild_Symptoms --> Idle
    [*] --> Active

Combination Prior Art Scenarios

Here are at least three scenarios where US patent 12576080 can be combined with existing open-source standards to generate further prior art:

  1. Combination with Open-Source Nasal Spray Device Design Standards:

    • Scenario: A defensive disclosure detailing the integration of a varenicline nasal spray formulation (as described in US12576080) with an open-source hardware design for a metered-dose nasal spray pump, compliant with ISO 20072:2009 (Aerosol drug delivery device design requirements) or similar open-source medical device designs.
    • Description: The combined prior art describes a method of increasing tear production using intranasal varenicline, specifically delivered via a pump system built according to publicly available and open-source CAD files and specifications for a spring-actuated, metered-dose nasal spray pump. The open-source design would specify component materials (e.g., FDA-approved polypropylene for actuator, stainless steel spring) and manufacturing tolerances (e.g., 25 µL dose per actuation with <10% variability), ensuring its practical manufacturability. This disclosure explicitly renders the use of widely known nasal pump designs with varenicline, for the claimed purpose, obvious.

  2. Combination with Open-Source Electronic Health Record (EHR) Data Standards:

    • Scenario: A defensive disclosure outlining a system where patient adherence and symptomatic response to the intranasal varenicline treatment (as per US12576080) are recorded and automatically integrated into an electronic health record using HL7 FHIR (Fast Healthcare Interoperability Resources) open-source standards.
    • Description: This prior art describes a smart nasal spray device (containing varenicline) that logs each administration event (date, time, dose) and prompts the patient to record a symptom score (e.g., Visual Analog Scale for dryness) via a linked mobile application. This data is then formatted into FHIR resources (e.g., MedicationAdministration for dosing, Observation for symptom score) and transmitted securely to a healthcare provider's EHR system. This renders obvious any system for tracking compliance and patient-reported outcomes for intranasal varenicline using established open-source health data exchange protocols.

  3. Combination with Open-Source IoT Communication Protocols for Remote Patient Monitoring:

    • Scenario: A defensive disclosure describing a remote monitoring system for patients using the intranasal varenicline method, where a smart nasal device or an associated wearable sensor communicates patient-specific data via an MQTT (Message Queuing Telemetry Transport) open-source protocol.
    • Description: This prior art details a varenicline nasal spray device equipped with a low-power Bluetooth Low Energy (BLE) module that connects to a patient's smartphone. The smartphone acts as a gateway, collecting device usage data (e.g., number of actuations, time since last dose, battery level) and environmental data (e.g., ambient humidity). This data is then published to a secure MQTT broker, allowing authorized healthcare providers or caregivers to subscribe to specific patient data streams. This enables real-time monitoring of adherence and environmental factors that might influence dry eye, making the application of common open-source IoT messaging protocols to this therapeutic context obvious.

Generated 6/9/2026, 5:04:24 AM